Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Mol Cancer Res. 2017 Nov 8;16(2):322–332. doi: 10.1158/1541-7786.MCR-17-0454

Figure 3.

Figure 3

TROY co-immunoprecipitates with ErbB3 and with ErbB2. (A) The expression pattern profile of erbB family members in T98G, U87, LN-229, A172, SK-BR-3 and SK-OV-3 cells. Cell lysates were immunoblotted with the indicated antibodies. (B) TROY co-immunoprecipitates with ErbB2 in SK-BR-3 cells. SK-BR-3 cells were transfected with or without HA tagged TROY plasmid. Twenty-four hours after transfection, cells were lysed and immunoprecipitated with anti-ErbB2 antibody. Immunoprecipitates or whole cell lysate (WCL) were immunoblotted (IB) with the indicated antibodies. The positions of molecular standards are shown on the left (in KDa). (C) TROY co-immunoprecipitates with ErbB2 in Q293 cells. Q293 cells were co-transfected with AU1 tagged ErbB2 plasmid plus/minus HA tagged TROY plasmid. Twenty-four hours after transfection, cells were lysed and immunoprecipitated with anti-AU1 antibody. Immunoprecipitates or whole cell lysate (WCL) were immunoblotted (IB) with the indicated antibodies. The positions of molecular standards are shown on the left (in KDa). (D) TROY co-immunoprecipitates with ErbB3 in LN229 cells. LN229 cells were transfected with either empty expression vector or HA-tagged TROY plasmid. Twenty-four hours after transfection, cells were lysed and immunoprecipitated with anti-ErbB3 antibody. Immunoprecipitates or whole cell lysate (WCL) were immunoblotted (IB) with the indicated antibodies. The positions of molecular standards are shown on the left (in KDa).